First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-25

Press Release 22 December 2025 08:15:00 CEST Xinnate AB SmiLe Incubator at Medicon Village Scheelevägen 2 223 81 Lund, Sweden Email: [email protected] Website: www.xinnate.com Reg.No. 559201-3857 1 First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-25 Lund, 22 December 2025 Lund, Sweden – Xinnate AB today announces the publication of its first-in-human, open-label, single-arm clinical study evaluating the safety, tolerability, and systemic exposure of topically applied TCP-25, the company’s novel immunomodulatory peptide, in patients with Epidermolysis Bullosa (EB). In this Phase 1 study, topical administration of TCP-25 gel was safe and well tolerated in patients with dystrophic EB, with no detectable systemic uptake. Exploratory clinical assessments also showed a consistent reduction in open wound size in TCP -25–treated wounds, indicating potential for accelerated wound healing. The full results are presented in the article “ Results of a Non -Randomized, Open-Label Phase I Study Evaluating the Novel Immunomodulatory Peptide TCP -25 for Treatment of Dystrophic Epidermolysis Bullosa ” by Karl Wallblom, Katja Holmgren, Sigrid Lundgren, Emma Belfrage, Torborg Hoppe, Matilda Hugerth, Anna -Karin Lindqvist, Enikö Sonkoly, and Artur Schmidtchen, published in Orphanet Journal of Rare Diseases: Link About TCP-25 TCP-25 is a novel immunomodulatory thrombin -derived C -terminal peptide with demonstrated anti-inflammatory, antimicrobial, and wound-healing properties. About TCP-25 gel Xinnate’s lead drug candidate, TCP -25 gel, is a topical formulation developed for the treatment of Epidermolysis Bullosa For more information Helene Hartman, CEO [email protected] Press Release 22 December 2025 08:15:00 CEST Xinnate AB SmiLe Incubator at Medicon Village Scheelevägen 2 223 81 Lund, Sweden Email: [email protected] Website: www.xinnate.com Reg.No. 559201-3857 2 About Xinnate AB Xinnate is a clinical-stage pharmaceutical company pioneering novel therapies based on proprietary peptide technology. These therapies aim to address dysfunctional healing by targeting the interplay of microbial presence and inflammatory responses. With an ambitious development program, Xinnate is dedicated to transforming the lives of patients with Epidermolysis Bullosa and other inflammatory skin conditions. A three - part Phase 1 study of the first drug candidate, TPC-25 gel, has been completed, including a group of patients with Epidermolysis Bullosa. The STEP study, a phase 2 /3 study is planned to start before year end 2025. www.xinnate.com

The release as fetched from its publisher. xinnate.com ↗